Actively Recruiting
Choice of the Optimal Treatment Strategies for Mid-low Rectal Cancer A National Multi-center, Prospective, Real World Study
Led by Peking Union Medical College Hospital · Updated on 2023-08-28
3705
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to compare different treatment methods for mid-low rectal cancer across various medical centers in China. The study focuses on evaluating treatment effectiveness, patient outcomes, and the economic impact of these treatments. The goal is to identify the best treatment approach that meets the needs of different medical units and to provide evidence-based recommendations for medical quality control and clinical guidelines. Participants diagnosed with mid-low rectal adenocarcinoma, confirmed by pathology and located within 12 cm of the anal verge, are observed without specific interventions assigned by the study. This is a registry study collecting real-world data from multiple centers to analyze treatment practices and outcomes. The study will track patients over time to assess survival rates and other key clinical outcomes. Throughout the study, researchers will monitor several important outcomes, including 3-year overall survival, disease-free survival, local recurrence, and distant metastasis rates. They will also evaluate the use of neoadjuvant and adjuvant therapies, imaging assessments, surgical success rates, and mortality within 30 days after surgery. The study helps inform medical decisions and insurance planning by analyzing treatment costs and benefits based on real-world patient data.
CONDITIONS
Brief Title
Choice of the Optimal Treatment Strategies for Mid-low REctal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed rectal adenocarcinoma
- Tumor located within 12 centimeters below the anal verge
You will not qualify if you...
- Diagnosed with distant metastasis
- Multiple primary colorectal cancers
- History of previous malignant tumors
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 3 years
Participants who undergo routine care for mid-low rectal cancer are observed over time to collect health outcomes and treatment data.
Periodic assessments during routine clinical visits
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
Research Team
Y
Yi Xiao, Professor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here